Grafalon

DRUG4 trials

Sponsors

St. Anna Kinderkrebsforschung, University Hospital, Brest, Fundación Canaria de Investigación Sanitaria, Assistance Publique - Hôpitaux de Paris

Conditions

Acute Lymphoblastic LeukaemiaGVHDKidney Transplant Failure and RejectionRenal Transplantation

Phase 2

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

RecruitingNCT01949129

St. Anna KinderkrebsforschungAcute Lymphoblastic Leukaemia

Start: 2013-04-30End: 2030-04-30Target: 1800Updated: 2024-01-16

Phase 3

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

Not yet recruitingNCT06083129

Assistance Publique - Hôpitaux de ParisGVHD

Start: 2023-11-01End: 2028-11-01Target: 324Updated: 2023-10-13

Phase 4

Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)

Fundación Canaria de Investigación SanitariaKidney Transplant Failure and Rejection

Start: 2022-07-05End: 2024-06-30Target: 80Updated: 2023-12-05

Unknown Phase

Comparison Thymoglobulin® and Grafalon®

University Hospital, BrestRenal Transplantation

Start: 2019-05-22End: 2021-11-22Target: 300Updated: 2020-07-07

Related Papers

Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.

2026-03-04

Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.

2025-11-19

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

Blood Advances2024-11-272 citations

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Blood2024-11-05

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Blood2023-11-02

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Blood2023-11-02

Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study

Blood Advances2023-09-2211 citations

Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

BMC Nephrology2022-11-072 citations

Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study

Journal of Clinical Oncology2020-12-17307 citations